Shaham’s irresistible playing of Dvořák’s Violin Concerto in A Minor was part of a Cincinnati Symphony Orchestra program that ...

One of the Minnesota Vikings' longest-tenured players, fullback C.J. Ham's body has taken its toll from the 2024 season. The ...

Johnson & Johnson (J&J) MedTech has reported a 4.8% growth in global sales in 2024, though it expects its 2025 outlook to remain affected by weak demand in China. J&J MedTech generated sales of $ ...

Johnson & Johnson (NYSE:JNJ) fell ~3% in early trading on Wednesday, marking its biggest intraday drop since July 2023, even as the healthcare giant posted better-than-expected financials for Q4 ...

J&J said that about a third of adults will not respond to oral antidepressants alone. Sign up here to get The Results Are In with Dr. Sanjay Gupta every Friday from the CNN Health team.

Spravato was already available in the market before today's FDA approval and has already proven to be a financial success for J&J but only as an adjunct therapy to oral antidepressants for TRD.

Currently, marketing of the product in Japan is conducted by Janssen Pharma, a J&J subsidiary. All the news that moves the needle in pharma and biotech Exclusive features, podcasts, interviews, data ...